Star source multi trade Limited has issued a formal clarification to the Bombay Stock Exchange regarding recent price movements in its shares. The company, formerly known as Chemo Pharma Laboratories Limited, submitted its response on April 01, 2026, addressing BSE's inquiry about share price fluctuations.

Company's Official Response

In its communication to BSE, Starsource Multitrade Limited clarified that it has consistently informed the exchange of all events and information impacting the company's operations and performance. The company emphasized its adherence to disclosure requirements under applicable regulations.

Regulatory Compliance Statement

The company stated that all price-sensitive information has been disclosed as required under Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. Management attributed the share price movement to market forces rather than any undisclosed corporate developments.

Management's Position

Ruchit Mehta, Managing Director and Chief Executive Officer, signed the response digitally. The company reiterated its commitment to maintaining transparency and keeping the stock exchange informed of any material events as and when they occur. The management emphasized that the price movement is purely market-driven and not related to any undisclosed information.

Ongoing Compliance Commitment

Starsource Multitrade Limited reaffirmed its adherence to SEBI (LODR) Regulations, 2015, particularly Regulation 30 requirements. The company assured BSE that it will continue to provide timely disclosure of all material information and events that could impact investor decisions or share price movements.

Star source multi trade Limited (formerly Chemo Pharma Laboratories Limited) announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved these results during their meeting held on February 12, 2026, at the company's registered office. The meeting commenced at 12:00 PM and concluded at 12:45 PM.

Financial Performance Overview

The company's financial performance showed significant volatility during the reporting period. The quarterly results revealed a stark contrast between Q3 FY26 and the previous quarter, with notable changes in revenue generation and profitability.

Revenue and Income Analysis

The company reported zero revenue from operations in Q3 FY26, marking a complete decline from the ₹5,256.56 thousand recorded in Q2 FY26. This represents a significant operational challenge as the company had no operational income during the quarter. Other income also remained at zero, contributing to the overall revenue decline.

Expense Structure

Despite the absence of revenue, the company incurred total expenses of ₹865.11 thousand during Q3 FY26. The major expense components included employee benefits expense of ₹216.00 thousand and administrative & other expenses of ₹649.11 thousand, while finance costs and depreciation remained at zero.

Nine-Month Performance

For the nine months ended December 31, 2025, Star Source Multitrade Limited reported revenue from operations of ₹5,256.56 thousand, entirely generated in Q2 FY26. However, the company recorded a substantial net loss of ₹117,935.62 thousand for the nine-month period, primarily driven by administrative and other expenses totaling ₹118,955.38 thousand.

Earnings Per Share

The company's earnings per share (EPS) reflected the financial challenges, with basic and diluted EPS of ₹(0.58) for Q3 FY26, compared to ₹0.65 in Q2 FY26. For the nine-month period, the EPS stood at ₹(78.62), significantly lower than ₹4.55 recorded in the corresponding period of the previous year.

Corporate Governance and Compliance

The financial results were reviewed by the Audit Committee and approved by the Board of Directors on February 12, 2026. The limited review report was prepared by S S R V & Associates, Chartered Accountants (Firm Registration No. 105017). The company operates as a single-segment entity with no subsidiary companies, maintaining a simplified corporate structure. The results were announced under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, with the company trading under Script Id 506365 and ISIN INE320M01019.